Purine analogue 6-methylmercaptopurine riboside inhibits early and late phases of the angiogenesis process

Cancer Research

Volumn 59, Issue 10, 1999, Pages 2417-2424

  Presta, Marco ^a   Rusnati, Marco ^a   Belleri, Mirella ^a   Morbidelli, Lucia ^b   Ziche, Marina ^b   Ribatti, Domenico ^c  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINOPURINE; 6 METHYLTHIOINOSINE; ADENOSINE; MERCAPTOPURINE; PURINE DERIVATIVE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; HUMAN; HUMAN CELL; MORPHOGENESIS; NONHUMAN; PRIORITY JOURNAL; TOPICAL DRUG ADMINISTRATION; TUMOR REGRESSION; TUMOR VASCULARIZATION;

2-AMINOPURINE; 6-MERCAPTOPURINE; ADENOCARCINOMA; ADENOSINE; ALLANTOIS; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; AORTA; BRAIN; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CATTLE; CELLS, CULTURED; CHICK EMBRYO; CHORION; CORNEA; DEPRESSION, CHEMICAL; ENDOMETRIAL NEOPLASMS; ENDOTHELIUM, VASCULAR; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; METHYLTHIOINOSINE; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PHYSIOLOGIC; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RABBITS; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 0033563116     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Fan, T-P. D., Jaggar, R., and Bicknell, R. Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy. Trends Pharmacol. Sci., 16: 57-66, 1995.
2. Hawkins, M. J. Clinical trials of antiangiogenic agents. Curr. Opin. Oncol., 7: 90-93, 1995.
3. Calabresi, P., and Chabner, B. A. Chemotherapy of neoplastic diseases. In: A. Goodman Gilman, T. W. Rall, A. S. Nies, and P. Taylor (eds.), The Pharmacological Basis of Therapeutics, pp. 1202-1263. New York: Pergamon Press, 1990.
4. Sokoloski, J. A., and Sartorelli, A. C. Inhibition of mannose incorporation into glycoproteins and dolichol-linked intermediates of Sarcoma 180 cells by 6-methylmercaptopurine ribonucleoside. Int. J. Cancer, 39: 764-768, 1987.
5. Volonté, C., and Greene, L. A. 6-Methylmercaptopurine riboside is a potent and selective inhibitor of nerve growth factor-activated protein kinase. N. J. Neurochem., 58: 700-708, 1992.
6. Zinn, K., Keller, A., Whittemore, L-A., and Maniatis, T. 2-Aminopurine selectively inhibits the induction of β-interferon, c-fos, and c-myc gene expression. Science (Washington DC), 240: 210-213, 1988.
7. O'Dwyer, P. J., Hudes, G. R., Colofiore, J., Walczak, J., Hoffman, J., LaCreta, F. P., Comis, R. L., Martin, D. S., and Ozols, R. F. Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine riboside: optimization of 6-methylmercaptopurine riboside dose and schedule through biochemical analysis of sequential tumor biopsy specimens. J. Natl. Cancer Inst., 83: 1235-1240.
8. Stolfi, R. L., Colofiore, J. R., Nord, L. D., Koutcher, J. A., and Martin, D. S. Biochemical modulation of tumor cell energy: regression of advanced spontaneous murine breast tumors with a 5-fluorouracil-containing drug combination. Cancer Res., 52: 4074-4081, 1992.
9. Redei, I., Green, F., Hoffman, J. P., Weiner, L. M., Scher, R., and O'Dwyer, P. J. Phase II trial of PALA and 6-methylmercaptopurine riboside (MMPR) in combination with 5-fluorouracil in advanced pancreatic cancer. Invest. New Drugs, 12: 319-321, 1994.
10. Martin, D. S., Stolfi, R. L., Colofiore, J. R., Nord, L. D., and Sternberg, S. Biochemical modulation of tumor energy in vivo: II. A lower dose of adryamicin is required and a greater antitumor activity is induced when cellular energy is depressed. Cancer Invest., 12: 296-307, 1994.
11. Hageboutros, A., Hudes, G. R., Brennan, J., Green, F., Hoffman, J., LaCreta, F. P., Colofiore, J., Martin, D. S., Ozolos, R. F., and O'Dwyer, P. J. Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside. Cancer Chemother. Pharmacol., 37: 229-234, 1996.
12. Teicher, B. A., Holden, S. A., Ara, G., Alvarez Sotomayor, E., Huang, Z. D., Chen, Y-N., and Brem, H. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int. J. Cancer, 57: 920-925, 1994.
13. Teicher, B. A., Holden, S. A., Ara, G., Korbut, T., and Menon, K. Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma. Cancer Chemother. Pharmacol., 38: 169-177, 1996.
14. Teicher, B. A. A systems approach to cancer therapy. Cancer Metastasis Rev., 15: 247-272, 1996.
15. Fenselau, A., Wallis, K., and Kaiser, D. Studies on a new class of potential antiangiogenic agents: nucleoside antimetabolite drugs. Microvasc. Res., 22: 58-63, 1981.
16. Isacchi, A., Statuto, M., Chiesa, R., Bergonzoni, L., Rusnati, M., Sarmientos, P., Ragnotti, G., and Presta, M. A six-amino acid deletion in basic fibroblast growth factor dissociates its mitogenic activity from its plasminogen activator-inducing capacity. Proc. Natl. Acad. Sci. USA, 88: 2628-2632, 1991.
17. Bastaki, M., Nelli, E. E., Dell'Era, P., Rusnati, M., Molinari-Tosatti, M. P., Parolini, S., Auerbach, R., Ruco, L. P., Possati, L., and Presta, M. Basic fibroblast growth factor-induced angiogenic phenotype in mouse endothelium: a study of aortic and microvascular endothelial cell lines. Arterioscler. Thromb. Vasc. Biol., 17: 454-464, 1997.
18. Quarto, N., Talarico, D., Sommer, A., Florkiewicz, R., Basilico, C., and Rifkin, D. B. Transformation by basic fibroblast growth factor requires high levels of expression: comparison with transformation by hst/K-fgf. Oncogene Res., 5: 101-110, 1989.
19. Gualandris, A., Rusnati, M., Belleri, M., Nelli, E. E., Molinari-Tosatti, M. P., Bonardi, F., Parolini, S., Albini, A., Morbidelli, L., Ziche, M., Corallini, A., Possati, L., Vacca, A., Ribatti, D., and Presta, M. Basic fibroblast growth factor expression in endothelial cells: an autocrine mechanism for angiogenesis and angioproliferative diseases. Cell Growth Diff., 7: 147-160, 1996.
20. Presta, M., Maier, J. A. M., and Ragnotti, G. The mitogenic signaling pathway but not the plasminogen activator-inducing pathway of basic fibroblast growth factor is mediated through protein kinase C in fetal bovine aortic endothelial cells. J. Cell Biol., 109: 1877-1884, 1989.
21. Montesano, R., Pepper, M. S., Vassalli, J-D., and Orci, L. Phorbol ester induces cultured endothelial cells to invade a fibrin matrix in the presence of fibrinolytic inhibitors. J. Cell. Physiol., 132: 509-516, 1987.
22. Pepper, M. S., Montesano, R., Vassalli, J-D., and Orci, L. Chondrocytes inhibit endothelial sprout formation in vitro: evidence for involvement of a transforming growth factor-β. J. Cell Physiol., 146: 170-179, 1991.
23. Besser, D., Presta, M., and Nagamine, Y. Elucidation of a signaling pathway induced by FGF-2 leading to uPA gene expression in NIH 3T3 fibroblasts. Cell Growth Differ., 6: 1009-1017, 1995.
24. Ribatti, D., Urbinati, C., Nico, B., Rusnati, M., Roncali, L., and Presta, M. Endogenous basic fibroblast growth factor in the vascularization of the chick embryo chorioallantoic membrane. Dev. Biol., 170: 39-49, 1995.
25. Ribatti, D., Vacca, A., Gasparini, G., Loverro, G., Di Vagno, G., Iurlaro, M., Lotesoriere, C., Roncali, L., and Selvaggi, L. Endometrial hyperplasia and endometrial carcinoma induce a vasoproliferative response in the chick embryo chorioallantoic membrane. Int. J. Oncol., 8: 1149-1153, 1996.
26. Ziche, M., Morbidelli, L., Chouduri, R., Zhang, H-T., Donnini, S., Granger, H. J., and Bicknell, R. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J. Clin. Invest., 99: 2625-2634, 1997.
27. Presta M., Moscatelli, D., Joseph-Silverstein, J., and Rifkin, D. B. Purification from a human hepatoma cell line of a basic fibroblast growth factor-like molecule that stimulates capillary endothelial cell plasminogen activator production, DNA synthesis, and migration. Mol. Cell. Biol., 6: 4060-4066, 1986.
28. Sato, Y., and Rifkin, D. B. Autocrine activities of basic fibroblast growth factor: regulation of endothelial cell movement, plasminogen activator synthesis, and DNA synthesis. J. Cell Biol., 107: 1199-1205, 1988.
29. Kubota, Y., Kleinman, H. K., Martin, G. R., and Lawley, T. J. Role of laminin and basement membrane in the morphological differentiation of human endothelial cells into capillary-like structures. J. Cell Biol., 107: 1589-1598, 1988.
30. Knighton, D., Ausprunk, D., Tapper, D., and Folkman, J. Avascular and vascular phases of tumor growth in the chick embryo. Br. J. Cancer, 35: 347-356, 1977.
31. Benjamin, L. E., and Keshet, E. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: Induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc. Natl. Acad. Sci. USA, 94: 8761-8766, 1997.
32. Satake, S., Kuzuya, M., Ramos, M. A., Kanda, S., and Iguchi, A. Angiogenic stimuli are essential for survival of vascular endothelial cells in three-dimensional collagen lattice. Biochem. Biophys. Res. Commun., 244: 642-646, 1998.
33. Gallo, O., Masini, E., Morbidelli, L., Franchi, A., Fini-Storchi, I., Vergari, W. A., and Ziche, M. Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J. Natl. Cancer Inst., 90: 587-596, 1998.
34. Folkman, J. Tumor angiogenesis. Adv. Cancer Res., 43: 175-203, 1985.
35. Hanahan, D. Signaling vascular morphogenesis and maintenance. Science (Washington DC), 277: 48-50, 1997.
36. 1/2 activation in postcapillary endothelium. J. Biol. Chem., 273: 4220-4226, 1998.
37. Marino, M. W., Dunbar, J. D., Wu, L-W., Ngaiza, J. R., Han, H-M., Guo, D., Matsushita, M., Nairn, A. C., Zhang, Y., Kolesnick, R., Jaffe, E. A., and Donner, D. B. Inhibition of tumor necrosis factor signal transduction in endothelial cells by dimethylaminopurine. J. Biol. Chem., 27I: 28624-28629, 1996.
38. Giannini, G., Di Marcotullio, L., Zazzeroni, F., Alesse, E., Zani, M., T'Ang, A., Sorrentino, V., Screpanti, I., Frati, L., and Gulino, A. 2-Aminopurine unravels a role for pRB in the regulation of gene expression by transforming growth factor β. J. Biol. Chem., 272: 5313-5319, 1997.
39. Liotta, L. A., Steeg, P. S., and Stetler-Stevenson, W. G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell, 64: 327-336, 1991.
40. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other diseases. Nat. Med., 1: 27-31, 1995.